Nuvation Bio Inc-A 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number:001-39351 Nuvation Bio Inc. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of October 24, 2025, the registrant had342,833,433shares of Common Stock, $0.0001par value per share, outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will”and “would,” or the negative of these terms or other similar expressions intended to identify statements about the future. We havebased these forward-looking statements largely on our current expectations and projections about future events and financial trendsthat we believe may affect our business, financial condition and results of operations. These forward-looking statements include,without limitation, statements about: •our plans to develop and commercialize IBTROZITM(taletrectinib) and our other product candidates;•our ability to obtain regulatory approval of our current and future product candidates, and to maintain regulatoryapproval for IBTROZI and our future approved products;•our expectations regarding the potential market size and the rate and degree of market acceptance of IBTROZI and ourcurrent and future product candidates;•our ability to recognize the anticipated benefits of the Merger (as defined below), which may be affected by, amongother things, competition and our ability to grow and manage growth profitably;•the initiation, timing, progress and results of our current and future preclinical studies and clinical trials, as well as ourresearch and development programs;•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;•our ability to successfully acquire or in-license additional product candidates on reasonable terms;•our ability to maintain and establish collaborations or obtain additional funding;•our continued reliance on third parties to conduct clinical trials of our product candidates, and for the manufacture ofour product candidates for preclinical studies, clinical trials and commercial supply of IBTROZI;•our ability to fund our working capital requirements and expectations regarding the sufficiency of our capitalresources;•the implementation of our business model and strategic plans for our business and product candidates;•our intellectual property position and the duration of our patent rights;•developments or disputes concerning our intellectual property or other proprietary rights;•our expectations regarding government and third-party payor coverage and reimbursement;•our ability to compete in the markets we serve;•the impact of government laws and regulations and liabilities thereunder;•our need to hire additional personnel and our ability to attract and retain such personnel;•our ability to raise additional funding in the future; and•the anticipated use of our cash and cash equivalents. The foregoing list of forward-looking statements is not exhaustive. These statements speak only as of the date of thisreport and i